Observational studyFrontiers in endocrinology2021
Spectrum of Endocrine Dysfunction and Association With Disease Severity in Patients With COVID-19: Insights From a Cross-Sectional, Observational Study.
Observational study in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Unraveling the relationship between ACTH and cortisol levels in COVID-19 infections: A meta-analysis.PloS one · 2023Pooled it
- Thyroxine changes in COVID-19 pandemic: A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Endocrine complications of COVID-19: diabetes, musculoskeletal, thyroid, pituitary, adrenal, and gonadal disorders.Journal of the Endocrine Society · 2026Review
- New-onset adrenal insufficiency in COVID-19 patients without preexisting adrenal disease: A systematic review.Qatar medical journal · 2026Review
- Article
- Impact of COVID-19 on pituitary function: a cross-sectional study in southern Iran.BMC endocrine disorders · 2025Article
- Association of DHEAS levels with COVID19 severity, gender, age, comorbidities, and management strategies.Scientific reports · 2025Article
- A case of central diabetes insipidus after COVID-19 as a probable diagnosis of lymphocytic infundibulo-neurohypophysitis with positive anti-rabphilin-3A antibodies with review of literature.Endocrine journal · 2024Review
- Reversible central adrenal insufficiency in survivors of COVID-19: results from a 24-month longitudinal study.Endocrine connections · 2024Article
- The Growing Understanding of the Pituitary Implication in the Pathogenesis of Long COVID-19 Syndrome: A Narrative Review.Advances in respiratory medicine · 2024Review
- Evaluation of the hypothalamo-pituitary-adrenal axis during the post-COVID-19 period in patients treated with steroids during the illness.Archives of endocrinology and metabolism · 2023Article
- COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders.Endocrine · 2023Review
- Prognostic values of baseline cortisol levels and neutrophil to lymphocyte ratio in COVID-19.Journal of medical biochemistry · 2023Article
- Pituitary and SARS CoV-2: An unremitting conundrum.Best practice & research. Clinical endocrinology & metabolism · 2023Review
- The Influence of SARS-CoV-2 Infection on the Thyroid Gland.Biomedicines · 2023Review
- AVP deficiency (central diabetes insipidus) following immunization with anti-COVID-19 BNT162b2 Comirnaty vaccine in adolescents: A case report.Frontiers in endocrinology · 2023Article
- Neuroimmunoendocrinology of SARS-CoV 2 Infection.Biomedicines · 2022Review
- Is SARS-CoV-2 a Risk Factor of Bipolar Disorder?-A Narrative Review.Journal of clinical medicine · 2022Review
- The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel.International journal of molecular sciences · 2022Review
- [Androgenic status in men during COVID-19].Problemy endokrinologii · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Evidence on new-onset endocrine dysfunction and identifying whether the degree of this dysfunction is associated with the severity of disease in patients with COVID-19 is scarce. Patients and Methods: Consecutive patients enrolled at PGIMER Chandigarh were stratified on the basis of disease severity as group I (moderate-to-severe disease including oxygen saturation <94% on room air or those with comorbidities) (n= 35) and group II (mild disease, with oxygen saturation >94% and without comorbidities) (n=49). Hypothalamo-pituitary-adrenal, thyroid, gonadal axes, and lactotroph function were evaluated. Inflammatory and cell-injury markers were also analysed. Results: Patients in group I had higher prevalence of hypocortisolism (38.5 Conclusion: COVID-19 can involve multiple endocrine organs and axes, with a greater prevalence and degree of endocrine dysfunction in those with more severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.